BSC Inc.

Rapid City, SD, United States
Rapid City, SD, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.prnewswire.com

Perhaps one of the most surprising misconceptions? 154 million Americans believe nothing's really happening when they doze. Yet research shows the brain recharges during sleep and stays in an active state. Of those who believe sleep is passive, adults under the age of 50 (67%) are more likely to believe this compared to those older than 50 (51%.) This month, the Better Sleep Council redesigned and updated their website to better educate consumers and to debunk common sleep myths. "Most of us spend on average around 26+ years in bed, so it's important for consumers to have an unbiased, unbranded resource on sleep and how to find a mattress that will help them get their best rest," said Mary Helen Rogers, vice president of marketing and communications for ISPA. "Our newly launched website will help consumers get the information they need to do just that." About the BSC The Better Sleep Council is the consumer education arm of the International Sleep Products Association, the trade association for the mattress industry. With decades invested in improving sleep quality, the BSC educates consumers on the link between sleep and health, and the role of the sleep environment, primarily through www.bettersleep.org, partner support and consumer outreach. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-survey-uncovers-americans-still-believe-myths-about-sleep-300454196.html


News Article | May 16, 2017
Site: en.prnasia.com

KUALA LUMPUR, Malaysia, May 17, 2017 /PRNewswire/ -- Bangsar shoppers were treated to a beautifully curated beauty and fashion experience featuring brands from Switzerland, Monaco, Italy, USA, Australia, Hong Kong, Thailand to Kuala Lumpur at the maiden Bangsar Shopping Centre Beauty & Fashion Week that ran from 10-14 May 2017 #BSCBFW17. Organised by BR Property Holdings Sdn Bhd, the management of Bangsar Shopping Centre (BSC) - one of the longest standing boutique malls in the Klang Valley in collaboration with Hair Sponsor A Cut Above, Official Makeup Flormar Malaysia and Official Car; MINI Ingress Auto, #BSCBFW17 was a hive of style this Mother's Day weekend. And there's more to come this Ramadhan season! YB Tan Sri Dato Sri Ng Yen Yen (JP) was Guest of Honour at the Meng Beauty & Slimming Swiss Perfection boutique spa products catwalk showcase. Also spotted among the guests were Datin Soraya and power couple entrepreneur Roen Cian Nagapan and model / Miss Malaysia 2013 Carey Ng. Hong Kong-based Mita Tam Style Studio had models strut the catwalk in colour-coded elegant feminine frocks, while stylists from A Cut Above x ghd gave away hair secrets and students from LimKokWing University of Creative Technology's Fashion Club mixed fashion with a violin performance on Saturday 13 May. Sunday 14 May revealed Angie's Hari Raya gown collection, followed by a stream of beauties in black dresses wearing APM Monaco's jewellery pieces influenced by Monaco and the joie de vivre of the South of France. The Fiore Raya Collection by Kavita Sidhu, creative director and owner of K.Vita Boutique was a hit! Finally, models dressed in delightfully quirky styling from Squareroom, accessorised by Mori Pin brought the #BSCBFW17 catwalk to a close. What's in store for shoppers this year at Bangsar's neighbourhood mall? BSC will host a month-long Raya Bazaar from 26 May - 23 June, BSC Kids Carnival from 26 - 30 July, Seek & Keep Artisan Market + Food Festival from 25 - 27 August, Home & Living throughout September, Deepavali Celebration from 7 - 22 October, Seek & Keep Artisan Market + Halloween Celebration from 27 – 29 October and finally, the Christmas Bazaar from 24 November - 24 December 2017. All welcomed, entry is free. Visit www.bsc.com.my, LIKE us on Facebook.com/BangsarShoppingCentre, FOLLOW us on Instagram @BangsarShoppingCentre. Note to Editors: Hi-res photos for BSC Beauty & Fashion Week here: http://bit.ly/2qcAnAA Bangsar Shopping Centre, BSC (Organiser and Official Venue) KL's neighbourhood lounge, BSC is a living, breathing, contemporary lifestyle destination that is the nexus of Bangsar's community. Its success lies in its appeal to a cross section of people - from expats to generations of local families. Its cosmopolitan atmosphere generates a "sense of belonging" making it a home away from home and a must-visit destination for the city's urban crowd. Visit www.bsc.com.my. A Cut Above Salon (Official hair) Started by husband and wife team Winnie Loo and Richard Teo, A Cut Above has gone from a humble 428 square feet salon to a household name in the hair styling industry. Since 1979, the company has grown into Malaysia's more premier group of salons with an established hairdressing academy. They are definitely one of KL's best hair salons. Visit http://acutabove.com.my. Flormar Malaysia (Official makeup) Founded in Milan in Italy, the capital of the fashion industry, Flormar was acquired by the Şenbay Family in 1970 and began production in Turkey. Flormar became an indispensable brand for women with its yearly production of 120 million units, as well as its wide range of products consisting of blushes, foundations, eyeshadows, mascaras, lipsticks, nail polishes, accessories and skin care products. Flormar Colour Cosmetics Malaysia is distributed by Parkson Beauty Unlimited Sdn Bhd with booths at IOI City Mall Putrajaya, MyTown Shopping Centre in Maluri. Visit www.facebook.com/myflormarcolours.com. Passionately BMW & MINI. Ingress Auto is giving the BMW & MINI experience to all in the Klang Valley vicinity and beyond. Striking an impressive silhouette in the area of Damansara, Puchong and Bangsar, Ingress Auto's facade embodies the high standards of personalized care and excellent after sales service. Ingress Auto has come a long way from being a single outlet BMW dealer back in 2008, to a multi outlet dealer in 2014 that comprises of Ingress Auto Damansara (Sales & Service), Ingress Auto Puchong (Sales & Service), Ingress Auto Bangsar (MINI Showroom), Ingress Auto Kepong (Body & Paint) and Ingress Auto Puchong (Body & Paint). Now, together with BMW & MINI, we are even more committed to deliver driving pleasure without compromises. Visit http://www.ingressauto.com.my. "Mita Tam Style Studio" was established to cater to the medium and upscale range of clothing for the stylish women. Mita Tam's range of dress collection and exclusive personal style service, ensure that customers do not have to spend big to be dressed well.  "Style Studio" is added to the overall name to suggest that women can come to the boutique to learn about themselves and experiment with their personal style.  Mita Tam Style Studio opened its flagship boutique at Starhill in December 2011. With a clientele roster including royalties, celebrities, Puan Sris and Datins in an exclusive environment like Starhill, the company decided to bring the Mita Tam label closer to the general public by establishing a presence in BSC in October 2014. The owner that bears the boutique name, Mita Tam, is a Hong Kong resident, and is a graduate of the Nanjing Academy of Performing Arts.  She has been involved in the entertaining and fashion industry in Hong Kong for the last 20 years.  Ms. Tam is a trained vocalist and image consultant and had imparted her expertise as an image consultant to numerous Hong Kong actors, actresses, singers and models. Founded by Chong Meng Chew, a beautician with over 20 years of experience has been trained in skincare, anti-aging treatments and slimming, Meng Beauty & Slimming offers advanced Cellular Skincare in a luxurious, calming and pampering environment rejuvenate, relax and destress. A Swiss Perfection Spa Boutique, its treatments reflect exclusivity and competence from Swiss Perfection products which contain IRISA, the result of a scientific collaboration with Clinique La Prairie CLP Montreux, Switzerland. It contains intact and active cells of the Iris root. High in enzymes and proteins to confront the problems of premature aging, environment hazards and the stress of contemporary life. Abandon yourself to our exclusive state-of-the-art Swiss Cellular skincare, unique treatment methods and tailored massage techniques. KVITA is a fashion lifestyle brand that personifies the timeless elegance and innate style of its founder and designer Kavita Sidhu. Influenced by Monaco and the joie de vivre of the South of France, APM Monaco (Ariane Prette) is a much loved contemporary fashion jewellery brand with a touch of Monegasque flair. APM inspires dreams, APM is not based on consensus, APM is different. Named after founder Ariane Prette, APM Monaco was created in 1982 and made her mark first in producing pieces for many of the great names in the jewellery business. After 30 years of developing and perfecting traditional handcrafted quality jewellery, the Prette family, in 2001, decided to venture into the design-focused silver jewellery business and continues to carry on Ariane's legacy with the aim to make APM Monaco a modern yet timeless brand that fits perfectly with current market trends. The group has over 1200 collaborators, and has achieved ISO 9001-2000 quality standard, GSCP environmental and BSCI social certifications. The Inspiration for the Collection: A new collection is created each month, and each monthly collection given a name. It is formed around a theme inspired by the atmosphere of the times, the inspiration of the creative team and APM's foundations. Established in Malaysia in 2013, APM creates four original collections per month, a total of 48 collections per year, all of which are registered and protected. Today, APM is the most creative jewellery brand with over 150 stores worldwide. Visit us online at www.apm.mc. Squareroom is a multi-label fashion retailer specialising in a wide spectrum of ladies fashion. At Squareroom, clients are encouraged to express their individuality by creating their own unique looks with our wide range of merchandise. From fashion- forward fashionistas to demure conservative dressers to quirky boho hipsters, there's something for everyone at Squareroom. Mori Pin is a well-loved treasure trove offering an extensive range of deliciously quirky one-off items, crystal-encrusted jewellery for that bling-bling effect and hot on-trend must-haves. Apart from that, several sought-after brands like Lucas Jack from the UK and Jonathan Yun designer jewellery are also available exclusively at Mori Pin. To complement its selection of accessories and bags, Mori Pin has also recently started to carry carefully-curated apparel in limited quantities. This means our loyal followers can now walk out with a complete ensemble and make a grand entrance on the red carpet, at work or even at a girly gathering! Ready to take the world by storm, Limkokwing Fashion Club is a fun and glamorous take on the biggest international trends in the fashion industry. An exciting combination of urban flair and various ethnic influences. Limkokwing Fashion Club introduces innovative designs made with the comfort and well-being of the customer in mind. From studded caps, sequinned and leather fitted jackets, specially designed handbags, backpacks, accessories and basics like T-shirts and hoodies for both sexes, it seems the stylish crowd may now halt their search. Each piece carries the charm and sleek edge of contemporary fashion and reflects in its core what it takes to be a trendsetter and style icon of tomorrow. Visit https://www.limkokwing.net.


News Article | April 26, 2017
Site: www.prnewswire.com

Die Bewerber diese Jahr kämpfen um die begehrte Auszeichnung in einer von fünf Kategorien: Best Process Innovation, Best Shared Services Team, Excellence in Culture Creation, Excellence in Transformation und - die 2017 erstmals aufgeführte Kategorie - Excellence in Automation (unterstützt von Automation Anywhere). In diesen stark umkämpften Kategorien haben es Unternehmen wie Coca-Cola Hellenic, Tarmac, Sonae, Heathrow BSC und Shell in zwei Kategorien in die Shortlist geschafft. Zu weiteren nominierten Unternehmen gehören UPM, Siemens, Hexaware, Account NI, Vodafone, Maersk, Western Union, Société Générale, Wüstenrot & Württembergische, National Grid, Ericsson, WNS, Mas Legato, 3M und Lufthansa. Account NI, das Sieger-Unternehmen aus dem Vorjahr, wurde in der Kategorie Excellence in Transformation erneut in die Shortlist aufgenommen und hätte somit die Möglichkeit, den Award zum zweiten Mal in Folge zu gewinnen. Das Unternehmen muss sich mit Auftritten von Coca-Cola Hellenic, Hexaware, Shell and Sonae messen. Die Verleihung 2017 wird von Experten aus dem Bereich Shared Services beurteilt: Irina Chernousenko, Paul Bryanhill, Chris Gunning, George Connell, Ian Herbert, Mike Stops und Paul Theaker. Die Excellence Awards Ceremony wird anlässlich der alljährlichen Shared Services and Outsourcing Week - diese geht in die 17. Runde - abgehalten und zwar vom 15.-18. Mai 2017 - die Gewinner werden zu diesem Zeitpunkt bekanntgegeben. SSOW ist der erste europäische Shared Services-Event mit 580+ führenden Unternehmen aus den Bereichen Shared Services, GBS, Outsourcing and Transformation.


News Article | April 26, 2017
Site: www.prnewswire.com

The applicants this year are competing to win a coveted award in one of the 5 categories; Best Process Innovation, Best Shared Services Team, Excellence in Culture Creation, Excellence in Transformation, and the new for 2017 category, Excellence in Automation, sponsored by Automation Anywhere.  Across these highly competitive categories, Coca-Cola Hellenic, Tarmac, Sonae, Heathrow BSC and Shell have all made the shortlist in 2 categories, whilst other nominees include; UPM, Siemens, Hexaware, Account NI, Vodafone, Maersk, Western Union, Société Générale, Wüstenrot & Württembergische, National Grid, Ericsson, WNS, Mas Legato, 3M and Lufthansa. After winning in 2016, Account NI have found themselves on the shortlist for the Excellence in Transformation category once again, and could to win the award for a second year in a row. They are up against entries from Coca-Cola Hellenic, Hexaware, Shell and Sonae. The 2017 Awards are judged by experts in the Shared Services industry; Irina Chernousenko, Paul Bryanhill, Chris Gunning, George Connell, Ian Herbert, Mike Stops and Paul Theaker. The Excellence Awards Ceremony is hosted during the 17th Annual Shared Services & Outsourcing Week taking place on the 15th - 18th May 2017 where the winners will be announced. SSOW is the premier European Shared Services Event which hosts 580+ Shared Services, GBS, Outsourcing and Transformation leaders. For more information go to http://awards.ssoweek.com


News Article | April 26, 2017
Site: www.prnewswire.co.uk

The applicants this year are competing to win a coveted award in one of the 5 categories; Best Process Innovation, Best Shared Services Team, Excellence in Culture Creation, Excellence in Transformation, and the new for 2017 category, Excellence in Automation, sponsored by Automation Anywhere.  Across these highly competitive categories, Coca-Cola Hellenic, Tarmac, Sonae, Heathrow BSC and Shell have all made the shortlist in 2 categories, whilst other nominees include; UPM, Siemens, Hexaware, Account NI, Vodafone, Maersk, Western Union, Société Générale, Wüstenrot & Württembergische, National Grid, Ericsson, WNS, Mas Legato, 3M and Lufthansa. After winning in 2016, Account NI have found themselves on the shortlist for the Excellence in Transformation category once again, and could to win the award for a second year in a row. They are up against entries from Coca-Cola Hellenic, Hexaware, Shell and Sonae. The 2017 Awards are judged by experts in the Shared Services industry; Irina Chernousenko, Paul Bryanhill, Chris Gunning, George Connell, Ian Herbert, Mike Stops and Paul Theaker. The Excellence Awards Ceremony is hosted during the 17th Annual Shared Services & Outsourcing Week taking place on the 15th - 18th May 2017 where the winners will be announced. SSOW is the premier European Shared Services Event which hosts 580+ Shared Services, GBS, Outsourcing and Transformation leaders. For more information go to http://awards.ssoweek.com


NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain.  These presentations will be made by the Company’s collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic. Poster Presentation:    Date: May 4th through May 6th   Time: 8:00 am Location: Poster Presentation Section Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS) Additional details and content from these presentations will be available on the Company’s website on the day of the presentations. About Onconova Therapeutics, Inc. Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova’s lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.


NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain.  These presentations will be made by the Company’s collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic. Poster Presentation:    Date: May 4th through May 6th   Time: 8:00 am Location: Poster Presentation Section Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS) Additional details and content from these presentations will be available on the Company’s website on the day of the presentations. About Onconova Therapeutics, Inc. Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova’s lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.


NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain.  These presentations will be made by the Company’s collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic. Poster Presentation:    Date: May 4th through May 6th   Time: 8:00 am Location: Poster Presentation Section Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS) Additional details and content from these presentations will be available on the Company’s website on the day of the presentations. About Onconova Therapeutics, Inc. Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova’s lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.


News Article | May 8, 2017
Site: www.scientificcomputing.com

Product developers talk about time to market. Web service providers measure time to first byte. For James Lowey, the key metric is time to life. Lowey is CIO at the Translational Genomics Research Institute (TGen), a nonprofit focused on turning genomics insights into faster diagnostics and treatments that are more effective. TGen’s genetics research is being applied to rare childhood diseases, cancer, neurological disorders, diabetes and others. “We’ve got patients waiting,” Lowey told the panel audience. “We need to diagnose and treat them. They need results now, not in weeks or months. We’re working to accelerate the movement of insights from the bench to the bedside.” It’s no surprise that each new generation of processors helps organizations like TGen deliver genetic results—and clinical answers—more quickly. Lowey described TGen’s farm of Intel Xeon processor E5 v3 based Dell blade servers based on Intel Scalable System Framework (Intel SSF). Using the blade servers, TGen has reduced processing time for critical genomics processing tasks from two weeks to seven hours, making it fast enough to be clinically relevant. Digital imaging is another area where HPC-enabled speedups are advancing clinical care. Panelist Simon K. Warfield described innovative imaging techniques his team is applying to increase understanding of the brain’s complex circuitry. Dr. Warfield is the Thorne Griscom Professor of Radiology at Harvard Medical School and the founder and director of the Computational Radiology Lab (CRL) at Boston Children's Hospital. CRL is an Intel Parallel Computing Center that is modernizing the algorithms and data structures of medical image computing on Intel Xeon and Intel Xeon Phi processors. The lab is improving cache performance, vectorization performance and multi-threading performance, as well as creating more sophisticated imaging and modeling strategies. CRL can contribute to improved diagnosis and treatment of brain injuries, multiple sclerosis, depression, Alzheimer’s and many other conditions. Consider the novel technique CRL has developed to show more clearly water’s diffusion through the brain—and pinpoint hindrances and restrictions to its flow. In contrast to traditional image processing approaches, CRL’s diffusion-weighted imaging infers new parametric maps from data measurements. Its computational model includes tens or hundreds of 3D images—each up to 10 million pixels each—as its inputs. “This type of analysis is very computationally intensive,” Warfield said. “With the accelerated algorithm and the Intel Xeon Phi processors, we reduced the time needed from 48 hours to 15 minutes of calculations.” That speedup can translate to immediate benefits in for critically ill patients facing brain surgery. That’s because, as Warfield put it, “When you’re talking about surgical planning, life is a matter of time.” Recently, one of the hospital’s neurosurgery teams realized on a Friday that their patient’s conventional magnetic resonance scan was not clear enough to allow them to proceed with a planned brain resection. With the surgery-planning meeting scheduled for Monday, they requested emergency use of CRL’s diffusion imaging algorithm. The patient had a new scan Saturday evening, the data was processed on Sunday, and the information was ready for the team’s decision on Monday. The panel also highlighted precision medicine’s global reach—and its big data challenges. Fang Lin, Director of the Bioinformatics Center at BGI, described BGI’s use of the Lustre file system to help maintain storage performance as its data volumes grow. BGI is a global research leader as well as a provider of genetic testing products. It also operates the China National Genebank, putting it on the forefront of China’s five-year. BGI cranks 20 terabytes of sequencing data every day. The institute stores13petabytes of genomic data and uses a 10 petabyte file system comprising Intel Enterprise Edition for Lustre Software and open source technologies. Dr. David Torrents, a molecular biologist and research professor at the Barcelona Supercomputing Center, shone a spotlight on the importance of collaboration in advancing precision medicine. BSC provides resources to a variety of international centers and consortia. In addition, the institute conducts its own multidisciplinary research in computational biomedicine and related fields. BSC’s alliances also encompass a range of hospitals and medical centers, enabling it to validate and test its models and tools with data from clinical institutions. “We’re at an exciting moment,” Torrents said. “We are not just developing new solutions for personalized medicine, but now are beginning a pilot program in January 2017 to bring them together and apply them in clinical settings, beginning in Catalonia and then throughout Spain.” The panelists say continued leaps forward in precision medicine will come from faster and more sophisticated analysis of larger volumes of more varied data types. “What we want is a more holistic picture, and for that, it’s becoming absolutely critical to combine many diverse data types together for analysis,” said Lowey. To achieve that holistic picture, researchers want to use deep learning and other forms of artificial intelligence. They also want to apply those AI methods to genomic data in combination with imaging data, lifelong clinical records, population studies, environmental studies, and much more. Different aspects of the precision medicine workflow will have varying processing and storage requirements. So the push continues for faster performance with agile or heterogeneous platform architectures rather than a single “silver bullet” approach. The processors will continue as the primary workhorses, supplemented by embedded resources and FPGA accelerators for parts of the workflow. Distributed compute and storage resources will remain crucial, along with advances in applications and tools. As to the clinical impact of these holistic approaches, look no further than Boston Children’s Hospital. Noninvasive prenatal genomic testing can indicate whether a fetus has the risk factors that predispose it to be born with a malformed heart. If genetic testing shows these factors are present, data-intensive digital imaging can reveal whether the heart is actually deformed. By combining genomic with other medical data in this way, clinicians can provide peace of mind for worried parents-to-be, or help them plan for their child’s future. “We’re starting to connect the genetics that predisposes an individual to heart disease, with the imaging to see if the defect is present, and use that information to influence current treatment,” said Warfield. “That information can also help us plan for the child’s longer-term future. We can predict how they’ll do as teenagers and begin to plan accordingly.” Precision medicine is one of the most promising and meaningful applications of high-performance computing today. “It’s still early days, but we’re moving toward an exciting new era of predictive biology and personalized medicine,” said McManus. “Our panelists gave us a great taste of what’s on the horizon. With continued advances in platform technologies, artificial intelligence, and other areas, we create significant opportunities to increase the science of medicine and ultimately improve human health. Intel is excited to empower scientists and clinicians with technology innovations, resources and expertise as we collaborate to make this new era a reality.” Jan Rowell writes about technology trends in HPC, healthcare, life sciences, and other industries.


News Article | May 1, 2017
Site: www.biosciencetechnology.com

Digital imaging is another area where HPC-enabled speedups are advancing clinical care. Panelist Simon K. Warfield described innovative imaging techniques his team is applying to increase understanding of the brain’s complex circuitry. Dr. Warfield is the Thorne Griscom Professor of Radiology at Harvard Medical School and the founder and director of the Computational Radiology Lab (CRL) at Boston Children's Hospital. CRL is an Intel Parallel Computing Center that is modernizing the algorithms and data structures of medical image computing on Intel Xeon and Intel Xeon Phi processors. The lab is improving cache performance, vectorization performance and multi-threading performance, as well as creating more sophisticated imaging and modeling strategies. CRL can contribute to improved diagnosis and treatment of brain injuries, multiple sclerosis, depression, Alzheimer’s and many other conditions. Consider the novel technique CRL has developed to show more clearly water’s diffusion through the brain—and pinpoint hindrances and restrictions to its flow. In contrast to traditional image processing approaches, CRL’s diffusion-weighted imaging infers new parametric maps from data measurements. Its computational model includes tens or hundreds of 3D images—each up to 10 million pixels each—as its inputs. “This type of analysis is very computationally intensive,” Warfield said. “With the accelerated algorithm and the Intel Xeon Phi processors, we reduced the time needed from 48 hours to 15 minutes of calculations.” That speedup can translate to immediate benefits in for critically ill patients facing brain surgery. That’s because, as Warfield put it, “When you’re talking about surgical planning, life is a matter of time.” Recently, one of the hospital’s neurosurgery teams realized on a Friday that their patient’s conventional magnetic resonance scan was not clear enough to allow them to proceed with a planned brain resection. With the surgery-planning meeting scheduled for Monday, they requested emergency use of CRL’s diffusion imaging algorithm. The patient had a new scan Saturday evening, the data was processed on Sunday, and the information was ready for the team’s decision on Monday. The panel also highlighted precision medicine’s global reach—and its big data challenges. Fang Lin, Director of the Bioinformatics Center at BGI, described BGI’s use of the Lustre file system to help maintain storage performance as its data volumes grow. BGI is a global research leader as well as a provider of genetic testing products. It also operates the China National Genebank, putting it on the forefront of China’s five-year. BGI cranks 20 terabytes of sequencing data every day. The institute stores13petabytes of genomic data and uses a 10 petabyte file system comprising Intel Enterprise Edition for Lustre Software and open source technologies. Dr. David Torrents, a molecular biologist and research professor at the Barcelona Supercomputing Center, shone a spotlight on the importance of collaboration in advancing precision medicine. BSC provides resources to a variety of international centers and consortia. In addition, the institute conducts its own multidisciplinary research in computational biomedicine and related fields. BSC’s alliances also encompass a range of hospitals and medical centers, enabling it to validate and test its models and tools with data from clinical institutions. “We’re at an exciting moment,” Torrents said. “We are not just developing new solutions for personalized medicine, but now are beginning a pilot program in January 2017 to bring them together and apply them in clinical settings, beginning in Catalonia and then throughout Spain.” The panelists say continued leaps forward in precision medicine will come from faster and more sophisticated analysis of larger volumes of more varied data types. “What we want is a more holistic picture, and for that, it’s becoming absolutely critical to combine many diverse data types together for analysis,” said Lowey. To achieve that holistic picture, researchers want to use deep learning and other forms of artificial intelligence. They also want to apply those AI methods to genomic data in combination with imaging data, lifelong clinical records, population studies, environmental studies, and much more. Different aspects of the precision medicine workflow will have varying processing and storage requirements. So the push continues for faster performance with agile or heterogeneous platform architectures rather than a single “silver bullet” approach. The processors will continue as the primary workhorses, supplemented by embedded resources and FPGA accelerators for parts of the workflow. Distributed compute and storage resources will remain crucial, along with advances in applications and tools. As to the clinical impact of these holistic approaches, look no further than Boston Children’s Hospital. Noninvasive prenatal genomic testing can indicate whether a fetus has the risk factors that predispose it to be born with a malformed heart. If genetic testing shows these factors are present, data-intensive digital imaging can reveal whether the heart is actually deformed. By combining genomic with other medical data in this way, clinicians can provide peace of mind for worried parents-to-be, or help them plan for their child’s future. “We’re starting to connect the genetics that predisposes an individual to heart disease, with the imaging to see if the defect is present, and use that information to influence current treatment,” said Warfield. “That information can also help us plan for the child’s longer-term future. We can predict how they’ll do as teenagers and begin to plan accordingly.” Precision medicine is one of the most promising and meaningful applications of high-performance computing today. “It’s still early days, but we’re moving toward an exciting new era of predictive biology and personalized medicine,” said McManus. “Our panelists gave us a great taste of what’s on the horizon. With continued advances in platform technologies, artificial intelligence, and other areas, we create significant opportunities to increase the science of medicine and ultimately improve human health. Intel is excited to empower scientists and clinicians with technology innovations, resources and expertise as we collaborate to make this new era a reality.” Jan Rowell writes about technology trends in HPC, healthcare, life sciences, and other industries.

Loading BSC Inc. collaborators
Loading BSC Inc. collaborators